Browsing Department of Clinical Medicine by Journals "Multiple Sclerosis and Related Disorders"

Now showing items 1-9 of 9

    • Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS – A longitudinal correlation study 

      Skorve, Ellen; Lundervold, Astri J.; Torkildsen, Øivind; Riemer, Frank; Grüner, Renate; Myhr, Kjell-Morten (Journal article; Peer reviewed, 2023)
      Background: Cognitive impairment is common in patients with multiple sclerosis, even in the early stages of the disease. The Brief International Cognitive Assessment for multiple sclerosis (BICAMS) is a short screening ...

    • Cancer related mortality in multiple sclerosis. A population based cohort study 

      Grytten, Nina; Myhr, Kjell-Morten; Celius, Elisabeth Gulowsen; Benjaminsen, Espen; Midgard, Rune; Vatne, Anita; Aarseth, Jan Harald; Mannseth, Janne; Torkildsen, Øivind Fredvik Grytten (Journal article; Peer reviewed, 2023)
      Background: Cancer is a major cause of death, but how cancer influences mortality risk in Multiple Sclerosis (MS) is unclear. Objectives: Determine all-cause mortality and mortality following a cancer diagnosis among ...

    • Comorbidity in multiple sclerosis patients from Nordland County, Norway - validated data from the Norwegian Patient Registry 

      Benjaminsen, Espen; Myhr, Kjell-Morten; Torkildsen, Nina Agnethe Grytten; Alstadhaug, Karl Bjørnar (Journal article; Peer reviewed, 2021)
      Background: Knowledge of comorbid disorders is important to optimize therapy for multiple sclerosis (MS), but data are limited. The aim of this study was to assess comorbidity in persons with MS living in Nordland County ...

    • Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy 

      Rød, Brit Ellen; Wergeland, Stig; Bjørnevik, Kjetil Lauvland; Holmøy, Trygve; Ulvestad, Elling; Njølstad, Gro; Myhr, Kjell-Morten; Torkildsen, Øivind (Journal article; Peer reviewed, 2023)
      Background B cell depletion therapy is highly effective in relapsing-remitting multiple sclerosis (RRMS). However, the precise underlying mechanisms of action for its biological effects in MS have still not been clarified. ...

    • Incidence of cancer in multiple sclerosis before and after the treatment era– a registry- based cohort study 

      Grytten, Nina; Myhr, Kjell-Morten; Celius, Elisabeth Gulowsen; Benjaminsen, Espen; Kampman, Margitta T.; Midgard, Rune; Vatne, Anita; Aarseth, Jan H.; Riise, Trond; Torkildsen, Øivind (Journal article; Peer reviewed, 2021)
      Background: Whether disease-modifying therapies (DMTs) influence cancer in multiple sclerosis (MS) is uncertain. Objectives: Assess incidence of cancer diagnosis among Norwegian MS patients compared to the general ...

    • Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis 

      Wesnes, Kristin; Myhr, Kjell-Morten; Riise, Trond; Stokke, Silje Agnethe; Torkildsen, Øivind; Wergeland, Stig; Holmøy, Trygve; Midgard, Rune; Bru, Alla Nikolajevna S; Edland, Astrid; Eikeland, Randi; Gosal, Sonia; Harbo, Hanne Flinstad; Kleveland, Grethe; Sørenes, Yvonne; Øksendal, Nina; Bjørnevik, Kjetil Lauvland (Journal article; Peer reviewed, 2021)
      Background: Low vitamin D levels, tobacco use and high body mass index (BMI) have been linked to adverse disease outcomes in multiple sclerosis (MS), but their influence on long-term disability progression remains unclear. ...

    • Predictors of hospitalization due to infection in rituximab-treated MS patients 

      Karlowicz, Jakob Rishovd; Klakegg, Mattias; Aarseth, Jan Harald; Bø, Lars; Myhr, Kjell-Morten; Torgauten, Hilde Marie; Torkildsen, Øivind; Wergeland, Stig (Journal article; Peer reviewed, 2023)
      Background: Rituximab is extensively used off-label to treat multiple sclerosis (MS), and long-term vigilance for adverse events is needed. This study was conducted to determine frequencies and predictors of hematological ...

    • Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS 

      Vermersch, Patrick; Oh, Jiwon; Cascione, Mark; Oreja-Guevara, Celia; Gobbi, Claudio; Travis, Lori H.; Myhr, Kjell-Morten; Coyle, Patricia K. (Journal article; Peer reviewed, 2020)
      Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disease affecting the white and gray matter of the central nervous system. Several disease modifying therapies (DMTs) have been shown to significantly ...

    • A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS 

      Skorve, Ellen; Lundervold, Astri; Torkildsen, Øivind; Myhr, Kjell-Morten (Journal article; Peer reviewed, 2020)
      Background: Cognitive impairment is common in patients with multiple sclerosis (MS) and may occur at any stage and with any subtype of the disease. Screening and monitoring of cognitive function should therefore be implemented ...